Recent outcomes of liver transplantation for Budd Chiari Syndrome – a study of the European Liver Transplant Registry (ELTR) and affiliated centers
Edo Dongelmans,Nicole Erler,Rene Adam,Silvio Nadalin,Vincent Karam,Sezai Yilmaz,Claire Kelly,Jacques Pirenne,Koray Acarli,Michael Allison,Abdul Hakeem,Dhakshinamoorthy Vijayanand,Dzmitry Fedaruk,Oleg Rummo,Murat Kilic,Arno Nordin,Lutz Fischer,Alessandro Parente,Darius Mirza,William Bennet,Yaman Tokat,Francois Faitot,Barbara B. Antonelli,Gabriela Berlakovich,David Patch,Frederik Berrevoet,Marija Ribnikar,Theophile Gerster,Eric Savier,Salvatore Gruttadauria,Bo-Göran Ericzon,Andrés Valdivieso,Valentin Cuervas-Mons,Baltasar Perez Saborido,Roland S. Croner,Luciano De Carlis,Giulia Magini,Roberta Rossi,Irinel Popescu,Laze Razvan,Stefan Schneeberger,Hans Blokzijl,Laura Llado,Miguel Angel Gomez Bravo,Christophe Duvoux,Vladimír Mezjlík,Gabriel C. Oniscu,Kelsey Pearson,Murat Dayangac,Valerio Lucidi,Olivier Detry,Fernando Rotellar,Caroline den Hoed,Wojciech G. Polak,Sarwa Darwish Murad,
DOI: https://doi.org/10.1097/hep.0000000000000778
IF: 17.298
2024-02-15
Hepatology
Abstract:Background and aims: Management of Budd-Chiari Syndrome (BCS) has improved over the last decades. The main aim was to evaluate the contemporary post-liver transplant (LT) outcomes in Europe. Approach and results: Data from all transplanted patients from 1976-2020 was obtained from the European Liver Transplantation Registry (ELTR). Patients<16yrs, with secondary BCS or hepatocellular carcinoma were excluded. Patient- (PS) and graft survival (GS) before and after 2000 were compared. Multivariate Cox regression-analysis identified predictors of PS and GS after 2000. Supplementary data was requested from all ELTR-affiliated centers and received from 44. 808 patients were transplanted between 2000-2020. One-, five- and ten-year PS was 84%, 77% and 68% and GS was 79%, 70% and 62%, respectively. Both significantly improved, compared to outcomes before 2000 ( p <0.001). Median follow up was 50 months and re-transplantation rate was 12%. Recipient age (aHR:1.04,95%CI:1.02-1.06) and MELD-score (aHR:1.04,95%CI:1.01-1.06), especially above 30, were associated with worse PS, while male sex had better outcomes (aHR:0.63,95%CI:0.41-0.96). Donor age was associated with worse PS (aHR:1.01,95%CI:1.00-1.03) and GS (aHR:1.02,95%CI:1.01-1.03). In 353 patients (44%) with supplementary data, 33% had myeloproliferative neoplasm, 20% underwent TIPS pre-LT and 85% used anticoagulation post-LT. Post-LT anticoagulation was associated with improved PS (aHR:0.29,95%CI:0.16-0.54) and GS (aHR:0.48,95%CI:0.29-0.81). Hepatic artery thrombosis and portal vein thrombosis occurred in 9% and 7%, while recurrent BCS was rare (3%). Conclusion: LT for BCS results in excellent patient- and graft survival. Older recipient or donor age, and higher MELD are associated with poorer outcomes, while long-term anticoagulation improves both patient and graft outcomes.
gastroenterology & hepatology